This silicone gel contains niacinamide 4% and kojic acid 2%. It is available by prescription in a 30 g pump.

This combination is formulated in a silicone gel, and is formulated to support the care of both new and old scars. It contains a blend of silicones in a semipermeable polymer network and pracaxi oil, which is rich in skin-friendly fatty acids and lipids. The formula promotes a soothing and nurturing environment while providing long-lasting moisturization that protects the skin barrier and helps reduce water loss. Patients have used this silicone gel to help improve the appearance of scars, including keloid and acne scars.

Topical niacinamide (vitamin B3) may support scar treatment through several mechanisms, including stimulating fibroblast proliferation, increasing collagen synthesis, and improving skin elasticity [1, 2]. It also reduces oxidative stress, enhances skin barrier integrity by boosting ceramides and free fatty acids, and controls inflammatory signaling, helping to decrease redness and inflammation [1, 3, 4].

Kojic acid, an organic acid derived from the fermentation of fungi such as Aspergillus oryzae (called “Koji” in Japan), works by chelating copper ions at the active site of tyrosinase, the key enzyme in melanin synthesis. By inhibiting tyrosinase activity, kojic acid prevents melanin formation [5], and also has antioxidant properties that support depigmentation [6].

Silicone gel creates a semi-occlusive barrier, increases stratum corneum hydration, and alters cytokine-mediated signaling from keratinocytes to fibroblasts [7].

This silicone gel may be considered by providers treating patients who are concerned with scar appearance.

Scars develop as part of the wound healing process and vary by how the skin repairs itself. Hypertrophic scars are raised but remain within the wound boundaries and are linked to excessive extracellular matrix (ECM) deposition [8, 9]. Keloid scars extend beyond the original wound and can continue to grow, often recurring despite treatment. Atrophic scars appear sunken or depressed, commonly after acne or infections [10, 11]. Contracture scars tighten the skin and may restrict movement, especially after burns, while stretch marks (striae) occur when skin stretches rapidly, such as during pregnancy or weight gain. These scar types reflect disruptions in collagen synthesis, degradation, and remodeling, which shape their final appearance [8, 10, 12].

Clinical studies have shown that niacinamide improves skin texture, fine lines, and hyperpigmentation, which may indirectly enhance scar appearance [2, 4]. For clinical use, evidence suggests newer scars may respond better [2]. Overall, niacinamide shows promise as a supportive therapy for scar management, particularly for improving pigmentation and texture.

Topical kojic acid’s main benefit comes from reducing hyperpigmentation rather than remodeling scar tissue. Kojic acid is best suited as an adjunctive treatment for the pigmentation component of scars, offering improvements in color [5, 6].

Silicone-based products remain one of the most established topical options, improving hydration, modulating fibroblast activity, and normalizing collagen production [7]. Together, these agents can be integrated into a comprehensive topical approach: silicone as a foundation for scar remodeling and hydration, niacinamide for barrier repair and collagen support, and kojic acid for reducing pigmentation changes, offering providers a multi-mechanistic strategy to improve scar appearance.

1. PRESCRIBER & PATIENT INFORMATION

Prescribing clinician’s name, licensing information, address and contact information. Patients’ full name, date of birth, shipping address and contact information.

2. COMPLETE PRESCRIPTION INFORMATION

Include: drug, dosage, and dosage form, quantity, SIG, and refills if requested.

3. PRESCRIPTION TRANSMITTAL

Fax: (940) 382-2694
Phone: 940-382-6758 | Speak to a pharmacist
Escribe ID: 0903012660 or CARIE BOYD Pharmaceuticals

•  Select Medication from the drop-down menu (bulk ingredient or powder is OK)
•  Use the words Please Compound in the SIG or Comments section followed by the compounded medication you want to prescribe.

NOTE: If you cannot find the same strength or form, that’s OK, write exactly what you want into the SIG or Comments section. In most cases we’ll be able to custom compound the prescribed medication.

Store at controlled room temperature. Protect from light and freezing.

[1] Marques C, Hadjab F, Porcello A, Lourenço K, Scaletta C, Abdel-Sayed P, Hirt-Burri N, Applegate LA, Laurent A. Mechanistic Insights into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products. Antioxidants (Basel). 2024 Mar 30;13(4):425. doi: 10.3390/antiox13040425. PMID: 38671873; PMCID: PMC11047333.
[2] Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005 Jul;31(7 Pt 2):860-5; discussion 865. doi: 10.1111/j.1524-4725.2005.31732. PMID: 16029679.
[3] Wohlrab J, Kreft D. Niacinamide – mechanisms of action and its topical use in dermatology. Skin Pharmacol Physiol. 2014;27(6):311-5. doi: 10.1159/000359974. Epub 2014 Jun 27. PMID: 24993939.
[4] Bissett DL, Miyamoto K, Sun P, Li J, Berge CA. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004 Oct;26(5):231-8. doi: 10.1111/j.1467-2494.2004.00228.x. PMID: 18492135.
[5] Wawrzyk-Bochenek I, Rahnama M, Stachura M, Wilczyński S, Wawrzyk A. Evaluation of the Reduction of Skin Hyperpigmentation Changes under the Influence of a Preparation Containing Kojic Acid Using Hyperspectral Imaging-Preliminary Study. J Clin Med. 2023;12(7):2710. Published 2023 Apr 4. doi:10.3390/jcm12072710
[6] Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the safety assessment of Kojic acid as used in cosmetics. Int J Toxicol. 2010 Nov-Dec;29(6 Suppl):244S-73. doi: 10.1177/1091581810385956. PMID: 21164073.
[7] Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg. 2008 Jan;32(1):82-92. doi: 10.1007/s00266-007-9030-9. Epub 2007 Oct 30. PMID: 17968615.
[8] Kidzeru EB, Lebeko M, Sharma JR, Nkengazong L, Adeola HA, Ndlovu H, P Khumalo N, Bayat A. Immune cells and associated molecular markers in dermal fibrosis with focus on raised cutaneous scars. Exp Dermatol. 2023 May;32(5):570-587. doi: 10.1111/exd.14734. Epub 2023 Feb 20. PMID: 36562321; PMCID: PMC10947010.
[9] Pym K. Identifying and managing problem scars. Br J Nurs. 2006 Jan 26-Feb 8;15(2):78-82. doi: 10.12968/bjon.2006.15.2.20367. PMID: 16493282.
[10] Moon J, Yoon JY, Yang JH, Kwon HH, Min S, Suh DH. Atrophic acne scar: a process from altered metabolism of elastic fibers and collagen fibers based on transforming growth factor-β1 signaling. Br J Dermatol. 2019 Dec;181(6):1226-1237. doi: 10.1111/bjd.17851. Epub 2019 Jul 9. PMID: 30822364.
[11] Fabbrocini G, Annunziata MC, D’Arco V, De Vita V, Lodi G, Mauriello MC, Pastore F, Monfrecola G. Acne scars: pathogenesis, classification and treatment. Dermatol Res Pract. 2010;2010:893080. doi: 10.1155/2010/893080. Epub 2010 Oct 14. PMID: 20981308; PMCID: PMC2958495.
[12] Chawla S, Ghosh S. Regulation of fibrotic changes by the synergistic effects of cytokines, dimensionality and matrix: Towards the development of an in vitro human dermal hypertrophic scar model. Acta Biomater. 2018 Mar 15;69:131-145. doi: 10.1016/j.actbio.2018.01.002. Epub 2018 Jan 10. PMID: 29330036.